4-Ethoxy-1,1,2-trifluorobut-1-ene | 2021-77-4

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 乙烯基卤化物
• 英文名称: 4-Ethoxy-1,1,2-trifluorobut-1-ene
• CAS: 2021-77-4
• 化学式: C₆H₉F₃O
• mdl: MFCD00155787
• 分子量: 154.13
• InChiKey: SHZZRRYXRFZQBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Triazole compounds and methods of making and using the same
  申请人：Bhattacharjee Ashoke

  公开号：US20100016956A1

  公开（公告）日：2010-01-21

  The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. The compounds have the following structure: wherein T is the macrocyclic part.

  本发明提供了三唑大环化合物，作为治疗剂非常有用。更具体地说，这些化合物可用作抗感染、抗增殖、抗炎和促动力剂。化合物具有以下结构：其中T是大环部分。
• Triazole Compounds and Methods of Making and Using the Same
  申请人：Bhattacharjee Ashoke

  公开号：US20130065845A1

  公开（公告）日：2013-03-14

  The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.

  本发明提供了三唑大环化合物，其作为治疗剂具有用途。更具体地说，这些化合物可作为抗感染、抗增殖、抗炎和促动力剂使用。
• Novel aerosol formulation containing a polar fluorinated molecule
  申请人：——

  公开号：US20030194378A1

  公开（公告）日：2003-10-16

  The present invention relates to a stable pharmaceutical aerosol formulation intended for inhalation. The formulation contains an active substance, an aerosol propellant, a polar flurorinated molecule and an excipient. The preferred propellant is HFA 134a or HFA 227 or a mixture thereof.

  本发明涉及一种用于吸入的稳定药用气溶胶制剂。该制剂含有一种活性物质、一种气溶胶推进剂、一种极性氟化分子和一种赋形剂。优选的推进剂是 HFA 134a 或 HFA 227 或它们的混合物。
• NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE
  申请人：AstraZeneca AB

  公开号：EP1303258A1

  公开（公告）日：2003-04-23
• Triazole Compounds And Methods Of Making And Using The Same
  申请人：Melinta Therapeutics, Inc.

  公开号：US20180094016A1

  公开（公告）日：2018-04-05

  The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.